Krystal Biotech awards director 1,187 options

Krystal Biotech director Daniel Janney received new stock option and RSU grants that vest in 2027, aligning his compensation with future company performance.

Rhea-AI Filing Summary

Krystal Biotech, Inc. (KRYS) reported that director Daniel Janney received equity awards on September 14, 2026. He was granted 1,187 stock options with an exercise price of $340.03 per share, expiring on September 13, 2036, and 471 restricted stock units. Both the options and RSUs vest in full on September 14, 2027, subject to Mr. Janney’s continued service on the board and earlier vesting conditions described in the company’s Non-Employee Director Compensation Policy. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 1,658 shares

Grant/Award 2 txns

Insider JANNEY DANIEL

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	1,187	$0.00	$0.00
Grant/Award	Restricted Stock Award F2, F3	471	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,187 contracts (Direct); Restricted Stock Award — 471 contracts (Direct)

Footnotes (3)

1. F1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.
2. F2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
3. F3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Key Figures

Stock options granted: 1,187 options Option exercise price: $340.03 per share Option expiration date: September 13, 2036 +3 more

6 metrics

Stock options granted 1,187 options Granted to director Daniel Janney on September 14, 2026

Option exercise price $340.03 per share Exercise price of options granted September 14, 2026

Option expiration date September 13, 2036 Expiration of options granted to Daniel Janney

Restricted stock units granted 471 RSUs Restricted stock award to Daniel Janney on September 14, 2026

Total shares underlying new awards 1,658 shares 1,187 shares underlying options plus 471 shares underlying RSUs

Vesting date for options and RSUs September 14, 2027 Full vesting date, subject to continued board service and policy terms

Key Terms

Restricted stock unit ("RSU"), contingent right, Non-Employee Director Compensation Policy

3 terms

Restricted stock unit ("RSU") financial

"Each restricted stock unit ("RSU") represents a contingent right to receive"

contingent right financial

"represents a contingent right to receive one share of the Company's common"

Non-Employee Director Compensation Policy financial

"described in the Company's Non-Employee Director Compensation Policy as in"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did KRYS director Daniel Janney receive in this Form 4?

Director Daniel Janney received 1,187 stock options at an exercise price of $340.03 per share and 471 restricted stock units, each representing a right to one share of Krystal Biotech common stock, all granted on September 14, 2026.

When do Daniel Janney’s new KRYS stock options and RSUs vest?

Both the 1,187 stock options and the 471 restricted stock units granted to director Daniel Janney vest in full on September 14, 2027, subject to his continued service on Krystal Biotech’s board and earlier vesting in circumstances described in the Non-Employee Director Compensation Policy.

What is the exercise price and expiration date of Daniel Janney’s new KRYS stock options?

The stock options granted to Daniel Janney have an exercise price of $340.03 per share and expire on September 13, 2036, as reported in the Form 4 for Krystal Biotech.

How many KRYS shares could be issued from Daniel Janney’s new equity awards?

The grants to director Daniel Janney cover up to 1,187 shares of common stock underlying the stock options and 471 shares underlying the restricted stock units, for a total of 1,658 shares of Krystal Biotech common stock if fully vested and exercised or settled.

Are Daniel Janney’s KRYS transactions under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that no Rule 10b5-1 trading plan is reported in connection with these equity grant transactions for Krystal Biotech director Daniel Janney.

What conditions affect vesting of Daniel Janney’s KRYS RSUs and options?

Vesting of the stock options and restricted stock units is subject to Daniel Janney’s continued service on the board through September 14, 2027 and to earlier vesting in certain circumstances described in Krystal Biotech’s Non-Employee Director Compensation Policy effective on the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 08:01 PM Accepted by SEC EDGAR 09/16/2026 - 08:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JANNEY DANIEL

(Last) (First) (Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH PENNSYLVANIA 15203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$340.03	09/14/2026		A		1,187		(1)	09/13/2036	Common Stock	1,187	$0	1,187	D
Restricted Stock Award	(2)	09/14/2026		A		471		(3)	(3)	Common Stock	471	$0	471	D

Explanation of Responses:

1. The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

2. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

3. The RSUs vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.

Remarks:

	/s/ Krish Krishnan, as attorney-in-fact for Daniel Janney	09/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)